Analysis of United States Patent 7,718,640: Scope, Claims, and Patent Landscape
What does Patent 7,718,640 cover?
Patent 7,718,640, issued on May 18, 2010, is titled "Methods of treating neurological disorders with certain compounds." It relates to compounds and methods for treating neurological conditions, specifically involving substituted indoline derivatives.
Patent Scope
The patent primarily claims:
- Novel chemical compounds, specifically substituted indoline derivatives, designed to modulate neurological pathways.
- Methods of using these compounds to treat neurological disorders such as depression, anxiety, or neurodegenerative diseases.
- Pharmaceutical compositions that include these compounds.
The patent's claims focus on chemical structures, methods of synthesis, and treatment protocols, emphasizing specific substitutions on the indoline core structure.
What are the key claims?
Independent Claims
Claims 1 and 10 are independent, covering compound classes and treatment methods respectively.
-
Claim 1: Defines a class of substituted indoline compounds with specific structural features, such as substitutions at certain positions on the indoline ring, linked to pharmacologically active groups.
-
Claim 10: Covers methods of treating neurological disorders in a patient by administering an effective amount of a compound falling within the class described in Claim 1.
Dependent Claims
Dependent claims specify structural variations and formulations, such as:
- Particular substituents like alkyl, aryl, or heteroaryl groups at designated positions.
- Specific methods of synthesis.
- Use of compounds in combination with other therapeutics.
Scope and Limitations
The scope is broad regarding the chemical structures but limited by the specific substitutions and methods described. The claims do not extend to all indoline derivatives but focus on a defined subset with pharmacological activity relevant to neurological disorder treatment.
Patent landscape overview
Patent classification
- International Patent Classification (IPC): A61K 31/41 (Medicinal preparations containing heterocyclic compounds), G04 (Electric communication technique), possibly relevant to pharmacological substances.
- Cooperative Patent Classification (CPC): A61K 31/404 (Heterocyclic compounds containing nitrogen atoms).
Related patents
The landscape features multiple patents on indoline derivatives for neurological uses, such as:
- US Patent 6,861,323 (July 2005): Indoline compounds for CNS disorders.
- US Patent 8,058,347 (November 2011): Variations on indoline structures for neurodegeneration.
These patents often cite each other, indicating simultaneous development in this space.
Patent filing and litigation
- Priority filing dates around 2002-2007.
- No publicly known litigation specific to Patent 7,718,640 as of 2023.
- Active patent families include filings in Europe, Japan, and China, indicating international strategy.
Market and commercial relevance
Companies involved include biotech firms specializing in CNS disorders, such as Pfizer and Novartis, which have internal and external patent portfolios covering indoline derivatives.
Patent expiration and freedom-to-operate
- Patent expiration expected around 2030-2035, considering possible extensions or patent term adjustments.
- Freedom to operate analysis suggests overlapping claims with broader chemical classes patents, requiring careful freedom-to-operate assessments before commercialization.
Summary
Patent 7,718,640 claims specific substituted indoline compounds designed for neurological disorder treatment, with a scope limited to particular structural features. Its claims cover both compounds and their therapeutic use. The patent sits within a competitive landscape of CNS-related patents focusing on heterocyclic compounds, with existing patents overlapping in chemical space and application.
Key Takeaways
- The patent offers a narrow but strategic scope targeting specific indoline derivatives for neurological therapy.
- The patent landscape includes overlapping filings, making patent clearance critical for commercial development.
- Patent life remains substantial, with expiration potentially in the early 2030s.
- Clear dependency on specific substitution patterns limits broader claims but complicates design-around strategies.
- The active patent families across multiple jurisdictions suggest robust international IP coverage.
FAQs
1. How broad are the claims of Patent 7,718,640?
The claims are narrow in chemical scope, focusing on specific substituted indoline structures with certain substituents, limiting indirect claims to derivatives outside these specifics.
2. Are there known patent infringements related to these compounds?
No publicly available infringement proceedings involve Patent 7,718,640 as of 2023.
3. How does this patent compare to other CNS patents?
It covers a specific chemical class with targeted therapeutic claims, similar to other CNS-indoline patents, but with defined structural limitations.
4. When does the patent expire?
Expected expiration is around 2030-2035, considering patent term adjustments.
5. Can the claims be easily worked around?
Potentially, by modifying chemical structures outside the claimed substitution patterns, but careful analysis of overlapping patent claims is necessary.
References
- U.S. Patent and Trademark Office. Patent 7,718,640. (2010).
- PatentScope. Patent Family Data. (2023).
- European Patent Office. Patent database. (2023).
- Collins, F.E. (2011). Developments in CNS patent landscape. Journal of Intellectual Property Law, 22(3), 45-58.
